Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$29.71 USD
-0.27 (-0.90%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $29.66 -0.05 (-0.17%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Balance Sheet
Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 353 | 323 | 234 | 229 | 24 |
Receivables | 74 | 55 | 35 | 22 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 4 | 4 | 4 | 1 |
Other Current Assets | 18 | 18 | 11 | 8 | 2 |
Total Current Assets | 451 | 400 | 284 | 263 | 32 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | 72 | 23 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 144 | 86 | 0 | 0 | 0 |
Intangibles | 137 | 161 | 144 | 162 | 72 |
Deposits & Other Assets | 7 | 4 | 4 | 1 | 2 |
Total Assets | 811 | 674 | 433 | 427 | 107 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 4 | 1 | 3 | 6 |
Current Portion Long-Term Debt | 15 | 2 | 2 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 123 | 71 | 49 | 132 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 2 | 1 | 0 | 0 |
Total Current Liabilities | 164 | 79 | 54 | 135 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 179 | 190 | 190 | 194 | 98 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 3 | 3 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 344 | 271 | 247 | 330 | 118 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 411 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 610 | 675 | 640 | 585 | 0 |
Retained Earnings | -143 | -272 | -454 | -488 | -423 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 467 | 403 | 187 | 97 | -12 |
Total Liabilities & Shareholder's Equity | 811 | 674 | 433 | 427 | 107 |
Total Common Equity | 467 | 403 | 187 | 97 | -423 |
Shares Outstanding | 58.50 | 59.30 | 58.40 | 56.80 | NA |
Book Value Per Share | 7.98 | 6.79 | 3.19 | 1.71 | 0.00 |
Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 372 | 353 | 371 | 371 | 344 |
Receivables | 80 | 74 | 67 | 64 | 53 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 5 | 5 | 5 | 4 |
Other Current Assets | 22 | 18 | 20 | 16 | 18 |
Total Current Assets | 480 | 451 | 463 | 456 | 418 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 0 |
Investments & Advances | 81 | 72 | 68 | 59 | 49 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 148 | 144 | 100 | 94 | 89 |
Intangibles | 131 | 137 | 143 | 149 | 155 |
Deposits & Other Assets | 7 | 7 | 3 | 3 | 4 |
Total Assets | 847 | 811 | 778 | 760 | 715 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 18 | 7 | 7 | 6 |
Current Portion Long-Term Debt | 15 | 15 | 15 | 11 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 99 | 123 | 83 | 72 | 63 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 8 | 8 | 4 | 10 |
Total Current Liabilities | 154 | 164 | 112 | 93 | 85 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 175 | 179 | 182 | 180 | 185 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 1 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 332 | 344 | 296 | 275 | 272 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 621 | 610 | 652 | 694 | 686 |
Retained Earnings | -105 | -143 | -170 | -208 | -243 |
Other Equity | 0 | 0 | -1 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 515 | 467 | 481 | 485 | 443 |
Total Liabilities & Shareholder's Equity | 847 | 811 | 778 | 760 | 715 |
Total Common Equity | 515 | 467 | 481 | 485 | 443 |
Shares Outstanding | 56.70 | 58.50 | 58.50 | 60.00 | 59.90 |
Book Value Per Share | 9.09 | 7.98 | 8.23 | 8.09 | 7.40 |